FDMT: 4D Molecular Therapeutics Inc

FDMT新闻

• 12:06 General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
• 12:05 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
• 12:26 Chardan Capital维持对4D Molecular Therapeutics的买入评级，将目标价下调至25美元
• 12:26 Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25
• 21:27 4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial
• 12:23 B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33
• 12:23 B of A证券维持对4D Molecular Therapeutics的买入评级，将目标价上调至33美元
• 12:03 4D Molecular Therapeutics Announces First Patients Enrolled In Phase 3 Trial Of 4D-150 In Diabetic Macular Edema; 2-Year Data Show 61% Fewer Injections
• 12:03 学术发表负面Q1业绩，加入Legacy Education、Zscaler和其他大股票在周五盘前交易中下跌
• 12:03 Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
• 14:48 4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
• 02:01 4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
• 22:05 4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
• 12:15 MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates